Treatment of euvolemic hyponatremia in the intensive care unit by urea

Guy Decaux, Caroline Andres, Fabrice Gankam Kengne, Alain Soupart, Guy Decaux, Caroline Andres, Fabrice Gankam Kengne, Alain Soupart

Abstract

Introduction: Hyponatremia in the intensive care unit (ICU) is most commonly related to inappropriate secretion of antidiuretic hormone (SIADH). Fluid restriction is difficult to apply in these patients. We wanted to report the treatment of hyponatremia with urea in these patients.

Methods: Two groups of patients are reported. The first one is represented by a retrospective study of 50 consecutive patients with mild hyponatremia treated with urea. The second group is presented by a series of 35 consecutive patients with severe hyponatremia acquired outside the hospital (≤ 115 mEq/L) who where treated by isotonic saline and urea (0.5 to 1 g/kg/day), administered usually by gastric tube.

Results: In the first group with mild hyponatremia (128 ± 4 mEq/L) the serum sodium (SNa) increased to a mean value of 135 ± 4 mEq/L (P < 0.001) after two days of urea therapy (46 ± 25 g/day), despite a large fluid intake (> 2 L/day). The mean duration of urea therapy was six days (from 2 to 42 days). Six patients developed hyponatremia again once the urea was stopped, which necessitated its reintroduction. Six patients developed hypernatremia (maximum value 155 mEq/L). In the second group, SNa increased from 111 ± 3 mEq/L to 122 ± 4 mEq/L in one day (P < 0.001). All the patients with neurological symptoms made a rapid recovery. No side effects were observed.

Conclusions: These data show that urea is a simple and inexpensive therapy to treat euvolemic hyponatremia in the ICU.

Figures

Figure 1
Figure 1
Evolution of SNa and blood urea in 50 patients before and after urea therapy.
Figure 2
Figure 2
Evolution of SNa in 35 patients with severe hyponatremia treated by urea and isotonic saline. (a) Daily evolution of SNa (mean ± SD) in 35 patients with severe hyponatremia (≤ 115 mEq/L) treated with isotonic saline and urea (*P < 0.001 compared to Day 0). (b) Daily evolution of SNa (mean ± SD) in 12 patients with severe hyponatremia (≤ 115 mEq/L) who received the first day only isotonic saline (1 or 2 L). The addition of urea increased significantly SNa (*P < 0.01 compared to Day 0). (c) Evolution of SNa (mean ± SD) each four hours in 10 patients with severe hyponatremia treated with 1 L isotonic saline over 12 hr and urea (0.5 g/kg) (P < 0.01 compared to time 0).

References

    1. Palmer BF. Hyponatremia in the intensive care unit. Semin Nephrol. 2009;29:257–270. doi: 10.1016/j.semnephrol.2009.03.003.
    1. De Vita MV, Gardenswartz MH, Konecky A, Zabetakis PM. Incidence and etiology of hyponatremia in an intensive care unit. Clin Nephrol. 1990;34:163–166.
    1. Stelfox MT, Ahmed SB, Khandwala F, Zygun D, Shahpori R, Lauplan K. The epidemiology of intensive care unit-acquired hyponatremia and hypernatremia in medical-surgical intensice care units. Crit Care. 2008;12:R162. doi: 10.1186/cc7162.
    1. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170:294–302. doi: 10.1001/archinternmed.2009.513.
    1. Gross P, Marczewski T, Herbrig K. The vaptans ante portas: a status report. Nephrol Dial Transplant. 2009;24:1371–1373. doi: 10.1093/ndt/gfp034.
    1. Chen S, Jalandhara N, Battle D. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. Nat Clin Pract Nephrol. 2007;3:82–95. doi: 10.1038/ncpneph0401.
    1. Quitbnat F, Gross P. Vaptans and the treatment of water-retaining disorders. Semin Nephrol. 2006;26:234–243. doi: 10.1016/j.semnephrol.2006.02.003.
    1. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006;69:2124–2130. doi: 10.1038/sj.ki.5000432.
    1. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371:1624–1632. doi: 10.1016/S0140-6736(08)60695-9.
    1. Ghali JK, Koren MJ, Tayor JR, Brooks-Asplund E, Fan K, Long WA, Smith N. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patiens with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91:2145–2152. doi: 10.1210/jc.2005-2287.
    1. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med. 2001;110:582–584. doi: 10.1016/S0002-9343(01)00678-7.
    1. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27:447–457. doi: 10.1159/000106456.
    1. Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatremia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf) 2008;69:159–168. doi: 10.1111/j.1365-2265.2007.03149.x.
    1. Ananne D, Decaux G, Smith N. Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009;337:28–36. doi: 10.1097/MAJ.0b013e31817b8148.
    1. Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care. 2009;11:14–19. doi: 10.1007/s12028-008-9179-3.
    1. Velez JC, Dopson SJ, Sanders DS, Delay TA, Arthur JM. Intravenous conivaptan for the treatment of hyponatremia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant. 2010;25:1524–1531. doi: 10.1093/ndt/gfp731.
    1. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Salt Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112. doi: 10.1056/NEJMoa065181.
    1. Decaux G, Brimioulle S, Genette F, Mockel J. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med. 1980;69:99–106. doi: 10.1016/0002-9343(80)90506-9.
    1. Decaux G, Unger J, Brimioulle S, Mockel J. Hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. Rapid correction with urea, sodium chloride, and water restriction therapy. JAMA. 1982;247:471–474. doi: 10.1001/jama.247.4.471.
    1. Decaux G, Genette F. Urea for long-term treatment of the syndrome of inappropriate secretion of antidiuretic hormone. Br Med J (Clin Res Ed) 1981;283:1081–1083. doi: 10.1136/bmj.283.6299.1081.
    1. Decaux G, Soupart A. Treatment of symptomatic hyponatremia. Am J Med Sci. 2003;326:25–30. doi: 10.1097/00000441-200307000-00004.
    1. Decaux G, Musch W, Soupart A. Hyponatremia in the intensive care: from diagnosis to treatment. Acta Clinica Belgica. 2000;55:68–78.
    1. Decaux G, Schlesser M, Coffernils M, Prospert F, Namias B, Brimioulle S, Soupart A. Uric acid, anion gap and urea concentration in the diagnosis approach to hyponatremic patients. Clin Nephrol. 1994;42:102–108.
    1. Fenske W, Stork S, Koschker AC, Blechschmidt A, Lorenz D, Wortmann S, Allolio B. Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics. J Clin Endocrinol Metab. 2008;93:2991–2997. doi: 10.1210/jc.2008-0330.
    1. Javid M. Urea - new use of an old agent. Reduction of intracranial and intraocular pressure. Surg Clin North Am. 1958;38:907–928.
    1. Buckell M. Blood changes on intravenous administration of mannitol or urea for reduction of intracranial pressure in neurosurgical patients. Clin Sci. 1964;27:223–227.
    1. Kleeman CR, Daison H, Levin E. Urea transport in the central nervous system. Am J Physiol. 1962;203:739–747.
    1. Decaux G, Szyper M, Grivegnée A. Cerebral ventricular volume during hyponatremia. J Neurol Neurosurg Psychiatry. 1983;46:443–445. doi: 10.1136/jnnp.46.5.443.
    1. Porzio P, Halberthal M, Bohn D, Halperin ML. Treatment of acute hyponatremia: ensuring the excretion of a predictable amount of electrolyte-free water. Crit Care Med. 2000;28:1905–1910. doi: 10.1097/00003246-200006000-00037.
    1. Dorman HR, Sondheiner JH, Cadnapahornchai P. Mannitol induced acute renal failure. Medicine (Baltimore) 1990;69:153–159.
    1. Musch W, Decaux G. Treating the syndrome of inappropriate secretion of ADH with isotonic saline. QJM. 1998;91:749–753.
    1. Verhoeven A, Musch W, Decaux G. Treatment of the polydipsia-hyponatremia syndrome with urea. J Clin Psychiatry. 2005;66:1372–1375. doi: 10.4088/JCP.v66n1105.
    1. Kawai N, Ishikawa K, Nemoto K, Katano T, Takahashi S, Hori T, Asada T. Oral urea treatment for polydipsia-hyponatremia syndrome in patients with schizophrenia. J Clin Psychopharmacol. 2009;29:499–501. doi: 10.1097/JCP.0b013e3181b3b38c.
    1. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120:S1–S21. doi: 10.1016/j.amjmed.2007.09.001.
    1. Decaux G, Musch W. Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. Clin J Am Soc Nephrol. 2008;3:1175–1184. doi: 10.2215/CJN.04431007.
    1. Musch W, Thimpont J, Vandervelde D, Vanhaeverbeke I, Berghmans T, Decaux G. Combined fractional excretion of sodium and urea better predicts response to saline in hyponatremia than do usual clinical and biochemical parameters. Am J Med. 1995;99:348–355. doi: 10.1016/S0002-9343(99)80180-6.
    1. Soupart A, Stenuit A, Perier O, Decaux G. Limits of brain tolerance to daily increments in serum sodium in chronically hyponatremic rats treated by hypertonic saline or urea. Clin Sci (Lond) 1991;80:77–84.
    1. Soupart A, Penninckx R, Stenuit A, Decaux G. Azotemia (48 h) decreases the risk of brain damage in rats after correction of chronic hyponatremia. Brain Res. 2000;852:167–172. doi: 10.1016/S0006-8993(99)02259-3.
    1. Soupart A, Silver S, Schroeder B, Sterns R, Decaux G. Rapid (24-hour) reaccumulation of brain organic osmolytes (particularly myo-Inositol) in azotemic rats after correction of chronic hyponatremia. J Am Soc Nephrol. 2002;13:1433–1441. doi: 10.1097/.
    1. Soupart A, Schroeder B, Decaux G. Treatment of hyponatremia by urea decreases risks of brain complications in rats, a brain osmolyte contents analyses. Nephrol Dial Transplant. 2007;22:1856–1863. doi: 10.1093/ndt/gfm138.
    1. Soupart A, Penninckx R, Crenier L, Stenuit A, Perier O, Decaux G. Prevention of brain demyelination in rats after excessive correction of chronic hypontremia by serum sodium lowering. Kidney Int. 1994;45:193–200. doi: 10.1038/ki.1994.23.
    1. Soupart A, Penninckx R, Stenuit A, Decaux G. Reinduction of hyponatremia improves survival in rats with myelinolysis related neurologic symptoms. J Neuropathol Exp Neurol. 1996;55:594–601. doi: 10.1097/00005072-199605000-00011.
    1. Gankam Kengne F, Soupart A, Pochet R, Brion JP, Decaux G. Re-induction of hyponatremia after rapid overcorrection of hyponatremia reduces mortality in rats. Kidney Int. 2009;76:614–621. doi: 10.1038/ki.2009.254.
    1. Perianayagam A, Sterns RH, Silver SM, Grieff M, Mao R, Hix J, Konides R. DDAVP is effective in preventing and reversing inadevertent overcorrection of hyponatremia. Clin J Am Soc Nephrol. 2008;3:331–336. doi: 10.2215/CJN.03190807.
    1. Soupart A, Decaux G. Efficacy and tolerance of vaptans compared to urea for long-term treatment of patients with SIADH: a prospective study. Acta Clinica Belgica. 2009;64:563. (abstract)

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj